EUVIMEDEUVIMED entdecken
Crossref

Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities

Zhao Zeng iD, Jiao Lu iD, Jingjing Shang, Hongyin You, Qingrong Wang iD, Lijun Wen iD, Qian Wang iD, Wanhui Yan, Chunxiao Wu, Panfeng Wang, Lian Bai, Song Jin iD und 5 weitere

British Journal of Haematology · 2026-11 · 209 (5) · 2103-2116

DOI: 10.1111/bjh.70817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 19.09.2026. Verfasst von Zhao Zeng und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Multiple Myeloma, Chromosome Aberrations. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Translational Research Fund of National Clinical Research Center for Blood System Diseases, the Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperdiploidy (HRD) is the most common genetic subtype in multiple myeloma (MM) but with significant prognostic heterogeneity. In this integrated Single Nucleotide Polymorphism (SNP‐array) and Fluorescence In Situ Hybridization (FISH) analysis of 694 newly diagnosed Chinese MM patients, a modal chromosome count >49 predicted superior overall survival (OS, p = 0.0062) and progression‐free survival (PFS, p = 0.00037), outperforming other metrics. Gain of chromosome 3 was favourable for OS ( p = 0.0024) and PFS ( p = 0.00078). Notably, HRD improved OS in patients with isolated 1q21 + ( p = 0.011) but not in those harbouring high‐risk abnormalities (t(4;14), t(14;16), 17p − or 1p32 − ). The prognostic value of modal count was cytogenetic abnormality (CA)‐dependent: in HRD without high‐risk CAs, >49 conferred better OS ( p = 0.01) and PFS ( p = 0.001); in isolated 1q21 + , a favourable trend was observed; but no discrimination in other high‐risk CAs. Autologous haematopoietic stem cell transplantation (AHSCT) significantly improved OS ( p = 0.014) and showed a PFS trend ( p = 0.062) only in HRD patients without high‐risk CAs and with >49 chromosomes. In conclusion, modal chromosome count >49 and chromosome 3 gain are robust favourable markers in HRD. HRD provides survival benefit in isolated 1q21 + . FISH‐based detection of trisomy 3 may offer a rapid, economical alternative for risk assessment of HRD. AHSCT benefit is restricted to low‐risk HRD with higher ploidy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaChromosome AberrationsHumansFemaleMaleMiddle AgedIn Situ Hybridization, FluorescenceAgedPrognosisPolymorphism, Single NucleotideAdultRisk Assessment

Stichwörter der Autor:innen

SNP arrayautologous haematopoietic stem cell transplantationcytogenetic abnormalitieshyperdiploidymultiple myeloma

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Department of Haematology, Jingjiang People's Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, China.
  • Soochow Hopes Hematonosis Hospital, Suzhou, China.
  • Suzhou Canglang Hospital, Suzhou, China.

ORCID-Profile: Zhao Zeng, Jiao Lu, Qingrong Wang, Lijun Wen, Qian Wang, Song Jin, Chengcheng Fu

Förderung

  • Translational Research Fund of National Clinical Research Center for Blood System Diseases
  • the Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China
  • the priority academic program development of Jiangsu Higher Education Institution
  • the Open Project of Jiangsu Biobank of Clinical Resources

Zitieren

APA

Zeng, Z., Lu, J., Shang, J., You, H., Wang, Q., Wen, L., Wang, Q., Yan, W., Wu, C., Wang, P., Bai, L., Jin, S., Yan, L., Chen, S., Wu, D., Pan, J., & Fu, C. (2026). Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities. British Journal of Haematology, 209(5), 2103-2116. https://doi.org/10.1111/bjh.70817

Vancouver

Zeng Z, Lu J, Shang J, You H, Wang Q, Wen L, et al. Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities. British Journal of Haematology. 2026;209(5):2103-2116. doi:10.1111/bjh.70817

BibTeX
@article{Zeng2026,
  author = {Zeng, Zhao and Lu, Jiao and Shang, Jingjing and You, Hongyin and Wang, Qingrong and Wen, Lijun and Wang, Qian and Yan, Wanhui and Wu, Chunxiao and Wang, Panfeng and Bai, Lian and Jin, Song and Yan, Lingzhi and Chen, Suning and Wu, Depei and Pan, Jinlan and Fu, Chengcheng},
  title = {Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2103--2116},
  doi = {10.1111/bjh.70817}
}
Kostenlos starten →